Health
Novel Combinations Excite the R/R Hodgkin Lymphoma Treatment Landscape – Targeted Oncology
While the treatment of relapsed or refractory Hodgkin lymphoma has seen novel approaches in recent years improving outcomes for many patients, high-risk patients…
While the treatment of relapsed or refractory (R/R) Hodgkin lymphoma (HL) has seen novel approaches in recent years improving outcomes for many patients, high-risk patients develop progressive disease and have limited treatment options.1
Two studies presented during the 62nd American Society of Hematology Annual Meeting and Exposition explored new therapeutic strategies for this patient population. First, results from a phase 2 study (NCT04052997) suggest that camidanlumab tesirine (ADCT-301) can…
Continue Reading
